HCW Biologics Inc.

NASDAQ: HCWB · Real-Time Price · USD
5.95
-0.19 (-3.09%)
At close: Jun 05, 2025, 3:59 PM
6.09
2.43%
After-hours: Jun 05, 2025, 07:44 PM EDT

Company Description

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases.

The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.

It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia.

The company was incorporated in 2018 and is headquartered in Miramar, Florida.

HCW Biologics Inc.
HCW Biologics Inc. logo
Country United States
IPO Date Jul 20, 2021
Industry Biotechnology
Sector Healthcare
Employees 36
CEO Dr. Hing C. Wong Ph.D.

Contact Details

Address:
2929 North Commerce Parkway
Miramar, Florida
United States
Website https://www.hcwbiologics.com

Stock Details

Ticker Symbol HCWB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001828673
CUSIP Number 40423R105
ISIN Number US40423R1059
Employer ID 82-5024477
SIC Code 2834

Key Executives

Name Position
Dr. Hing C. Wong Ph.D. Founder, Chief Executive Officer, Director & Secretary
Dr. Peter Rhode Ph.D. Chief Scientific Officer & Vice President of Clinical Operations
Lee D. Flowers Senior Vice President of Business Development
Nicole Valdivieso Esq. Vice President of Legal Affairs

Latest SEC Filings

Date Type Title
Jun 04, 2025 8-K Current Report
May 30, 2025 8-K Current Report
May 23, 2025 8-K Current Report
May 20, 2025 4 Filing
May 20, 2025 4 Filing
May 20, 2025 4 Filing
May 20, 2025 8-K Current Report
May 15, 2025 10-Q Quarterly Report
May 15, 2025 8-K Current Report
May 15, 2025 8-K Current Report